ai3Bio Launches with $48 Million in Series A Funding to Reset the Immune System at Its Root
Platforms target and eliminate disease-causing Th17 cells in vivo, backed by lead investors UPMC Enterprises and Ziff Capital Partners
All Blog Posts
ai3Bio Launches with $48 Million in Series A Funding to Reset the Immune System at Its Root
Platforms target and eliminate disease-causing Th17 cells in vivo, backed by lead investors UPMC Enterprises and Ziff Capital Partners
Introducing ai3Bio: Resetting the immune system at its root
Today, ai3Bio launched with $48M to directly target and eliminate disease-causing Th17 cells at their source, in a single step.
